Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Adagene Licenses its mAb Masking Technology to Exelixis in Collaboration

publication date: Feb 4, 2021

Suzhou's Adagene will license its SAFEbody™ technology platform, which generates masked versions of monoclonal antibodies, to Exelixis for use in Exelixis’ ADC preclinical pipeline. Exelixis will make an upfront payment of $11 million to Adagene and will have the ability to nominate two targets during the collaboration. Adagene will be eligible for development and commercialization milestones, as well as royalties on net sales of any developed products. Exelixis is headquartered in Alameda, CA. More details....

Stock Symbol: (NSDQ: EXEL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.